HomeCompareORPOF vs JEPI

ORPOF vs JEPI: Dividend Comparison 2026

ORPOF yields 17.24% · JEPI yields 8.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPOF wins by $32.6K in total portfolio value
10 years
ORPOF
ORPOF
● Live price
17.24%
Share price
$11.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$61.6K
Annual income
$4,960.97
Full ORPOF calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.40%
Share price
$56.68
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$1,528.62
Full JEPI calculator →

Portfolio growth — ORPOF vs JEPI

📍 ORPOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPOFJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPOF + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORPOF pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPOF
Annual income on $10K today (after 15% tax)
$1,465.52/yr
After 10yr DRIP, annual income (after tax)
$4,216.82/yr
JEPI
Annual income on $10K today (after 15% tax)
$714.16/yr
After 10yr DRIP, annual income (after tax)
$1,299.33/yr
At 15% tax rate, ORPOF beats the other by $2,917.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPOF + JEPI for your $10,000?

ORPOF: 50%JEPI: 50%
100% JEPI50/50100% ORPOF
Portfolio after 10yr
$45.3K
Annual income
$3,244.80/yr
Blended yield
7.17%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPOF buys
0
JEPI buys
0
No recent congressional trades found for ORPOF or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPOFJEPI
Forward yield17.24%8.40%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$61.6K$29.0K
Annual income after 10y$4,960.97$1,528.62
Total dividends collected$32.3K$11.7K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ORPOF vs JEPI ($10,000, DRIP)

YearORPOF PortfolioORPOF Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$12,424$1,724.14$11,260$840.19+$1.2KORPOF
2$15,296$2,001.96$12,641$907.94+$2.7KORPOF
3$18,670$2,303.44$14,150$978.20+$4.5KORPOF
4$22,604$2,627.62$15,795$1,050.85+$6.8KORPOF
5$27,160$2,973.25$17,584$1,125.74+$9.6KORPOF
6$32,400$3,338.74$19,526$1,202.74+$12.9KORPOF
7$38,390$3,722.32$21,628$1,281.69+$16.8KORPOF
8$45,200$4,121.99$23,898$1,362.43+$21.3KORPOF
9$52,899$4,535.61$26,347$1,444.79+$26.6KORPOF
10$61,563$4,960.97$28,982$1,528.62+$32.6KORPOF

ORPOF vs JEPI: Complete Analysis 2026

ORPOFStock

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

Full ORPOF Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this ORPOF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPOF vs SCHDORPOF vs OORPOF vs KOORPOF vs MAINORPOF vs JEPQORPOF vs XYLDORPOF vs DIVOORPOF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.